Expression of gemcitabine-and cisplatin-related genes in non-small-cell lung cancer

Pharmacogenomics Journal

Volumn 10, Issue 3, 2010, Pages 180-190

  Toffalorio, F ^a   Giovannetti, E ^b   De Pas, T ^a   Radice, D ^a   Pelosi, G ^a,c   Manzotti, M ^a   Minocci, D ^b   Spaggiari, L ^a,c   Spitaleri, G ^a   Noberasco, C ^a   Catania, C ^a   Boselli, S ^a   Danesi, R ^b   De Braud, F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cisplatin; Gemcitabine; Gene expression; Histotype; NSCLC; Stage

Indexed keywords

5' NUCLEOTIDASE; CISPLATIN; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE REGULATORY SUBUNIT 1; RIBONUCLEOTIDE REDUCTASE REGULATORY SUBUNIT 2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CANCER STAGING; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

5'-NUCLEOTIDASE; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA-BINDING PROTEINS; ENDONUCLEASES; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

EID: 77952886846     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.53     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Rosell R, Cobo M, Isla D, Camps C, Massuti B. Pharmacogenomics and gemcitabine. Ann Oncol 2006; 17(Suppl 5): v13-v16.
4. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005; 50: 211-219.
5. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K et al. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 2008; 13: 510-517.
6. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
7. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55: 57-103.
8. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349-4357.
9. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equili-brative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-775.
10. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-3935.
11. Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006; 91: 895-902.
12. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253.
13. van Bree C, Castro Kreder N, Loves WJ, Franken NA, Peters GJ, Haveman J. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys 2002; 54: 237-244.
14. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371-376.
15. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-890.
16. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49: 363-370.
17. Kirch H-C, Schroder J, Hoppe H, Esche H, Seeber S, Schütte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26: 421-425.
18. Danesi R, Altavilla G, Giovannetti E, Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 2009; 10: 69-80.
19. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-1803.
20. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510-9516.
21. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59: 4204-4207.
22. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64: 3761-3766.
23. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10: 4215s-4219s.
24. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-4737.
25. Zheng Z, Chen T, Xueli L, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808.
26. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-192.
27. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008; 14: 3083-3088.
28. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ et al. Ribonucleotide reductase M1 (RRM1) 2464G4A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16: 429-438.
29. Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS et al. An association between RRM1 haplotype and gemcitabine-induced neu-tropenia in breast cancer patients. Oncologist 2007; 12: 622-630.
30. Sancar A. DNA repair in humans. Annu Rev Genet 1995; 29: 69-105.
31. Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui-Jamali MA. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995; 55: 4760-4764.
32. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291.
33. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-1825.
34. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
35. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109.
36. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
37. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-nä?ve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
38. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-263.
39. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.
40. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-1596.
41. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008; 3: 1468-1481.
42. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 2001; 280: 951-959.
43. Burgermeister R. New aspects of laser microdissection in research and routine. J Histochem Cytochem 2005; 53: 409-412.
44. Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008; 28: 2205-2212.
45. Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006; 5: 1800-1806.
46. Ganti AK, Parr A, Nguyen D, Grem JL. Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. Proc Am Soc Clin Oncol 2006; 24: 2007a.
47. Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 2005; 93: 35-40.
48. Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008; 27: 720-725.
49. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12: 1794-1803.
50. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-41.